An increasing body of subsequent research has challenged the usefulness of the healthcare-associated pneumonia label, including studies that have cast doubt on links between multidrug-resistant pathogens and increased mortality.
A multidisciplinary panel of experts put together by the American Thoracic Society and Infectious Diseases Society of America released updated recommendations for the management of adults with community-acquired pneumonia.
A shift toward personalized medicine in pneumonia management would involve refining the diagnostic categories to include viral pneumonia, bacterial pneumonia, and noninfectious respiratory disease.
Study authors described the prescribing patterns in children with community-acquired pneumonia, and assessed the relationship between narrow-spectrum antibiotics, broad-spectrum antibiotics, and macrolides with clinical outcomes.
Results from PNEU-PATH demonstrated comparable immune responses following vaccination with Pneumovax 23 in both treatment groups for the 15 serotypes in V114.
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens.
ICD-9 organism-specific administrative codes for pneumonia appear to underestimate the prevalence of specific disease-associated pathogens in hospitalized patients.
